[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"United Arab Emirates\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":728},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,120,0,25,[9,43,65,88,122,145,174,198,227,254,275,301,323,348,368,394,464,514,541,571,589,614,650,673,699],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100579098","phase-3-a-study-to-assess-the-efficacy-and-safety-of-induction-and-maintenance-therapy-with-afimkibart-ro7790121-in-participants-with-moderately-to-severely-active-crohns-disease-100579098",false,"NCT06819878","A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease","SIBERITE-1","Inclusion Criteria:\n\n* Confirmed diagnosis of CD\n* Moderately to severely active CD\n* Bodyweight \\>= 40 kilogram (kg)\n* Demonstrated inadequate response, loss of response and\u002For intolerance to at least one protocol-specified conventional or advanced CD therapy\n* Males and females of childbearing potential must meet protocol criteria for contraception requirements\n\nExclusion Criteria:\n\n* Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis\n* Participant with a history of \\>= 3 bowel resections (\\> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum)\n* Diagnosis of short gut or short bowel syndrome\n* Presence of an ileostomy, colostomy or ileoanal pouch\n* Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon\n* Presence of abdominal or perianal abscess\n* Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with \\>3 openings\n* Current diagnosis or suspicion of primary sclerosing cholangitis\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study\n* Any past or current evidence of cancer of gastrointestinal tract, definite low-grade or high-grade colonic dysplasia\n* History of non-gastrointestinal cancer, with the exception of adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer\n* Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV) during screening\n* Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB\n* Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy","ALL","16 Years","80 Years",{"count":22,"type":23},600,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).",[29],"Moderately to Severely Active Crohns Disease","RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2025-03-17",{"date":38,"type":23},"2033-12-31",{"name":40,"class":41},"Hoffmann-La Roche","INDUSTRY",372,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100550445","a-study-observing-everyday-effectiveness-and-safety-of-the-drug-elafibranor-in-participants-with-primary-biliary-cholangitis-who-are-receiving-ongoing-treatment-100550445","NCT06447168","A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment","Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg\u002FDay in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting.","ELFINITY","Inclusion Criteria:\n\n* Participant has provided written informed consent and agrees to comply with the study protocol.\n* Participant with PBC diagnosis.\n* Participant for whom the treating physician has decided to start or participants who are currently receiving treatment with commercialized elafibranor.\n* If a participant has a caregiver who agrees to complete the caregiver questionnaires, an informed consent should be collected from the caregiver before any data is collected.\n\nExclusion Criteria:\n\n* Participant is currently participating or, plans to participate in an investigational drug study or medical device study containing active substance.\n* Participant with known hypersensitivity to the product or to any of its excipients.\n* Participant with mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.",{"count":52,"type":23},424,"OBSERVATIONAL","This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting.\n\nPBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged.\n\nThe liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms including pruritus (itching) and fatigue. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.\n\nIn this study the main aim is to observe the effectiveness, safety and tolerability of elafibranor in participants with PBC who are receiving treatment in real world setting. The total study duration for each participants will be 60 months (approximately 5 years).",[56],"Primary Biliary Cholangitis",{"date":33,"type":34},{"date":59,"type":34},"2024-10-14",{"date":61,"type":23},"2032-07-15",{"name":63,"class":41},"Ipsen",68,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":18,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100534614","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-subcutaneous-amlitelimab-on-background-topical-corticosteroids-therapy-in-participants-aged-12-years-and-older-with-moderate-to-severe-ad-who-have-had-an-inadequate-response-to-prior-biologic-therapy-or-an-oral-jak-inhibitor-100534614","NCT06241118","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment","AQUA","Inclusion Criteria:\n\n* Participants must be 12 years of age (when signing informed consent form)\n* Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)\n* Documented history prior to screening visit of inadequate response to a biologic AD medication or an oral JAKi therapy.\n* v-IGA-AD of 3 or 4 at baseline visit\n* EASI score of 16 or higher at baseline\n* AD involvement of 10% or more of BSA at baseline\n* Weekly average of daily PP-NRS of ≥ 4 at baseline visit.\n* Able and willing to comply with requested study visits and procedures\n* Body weight ≥25 kg\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Skin co-morbidity that would adversely affect the ability to undertake AD assessments\n* Known history of or suspected significant current immunosuppression\n* Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured \\>5 years prior to baseline)\n* History of solid organ or stem cell transplant\n* Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline\n* Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit\n* Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB\n* Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit\n* In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening\n* History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial","12 Years",{"count":75,"type":23},636,[26],"This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy.\n\nThe purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy.\n\nStudy details include:\n\nAt the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD).\n\nThe study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \\[RIVER-AD\\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up.\n\nThe study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \\[RIVER-AD\\]) including a 2 to 4-week screening and a 36-week randomized double-blind period.\n\nThe total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \\[RIVER-AD\\] study).",[79],"Dermatitis Atopic",{"date":33,"type":34},{"date":82,"type":34},"2024-02-29",{"date":84,"type":23},"2028-09-29",{"name":86,"class":41},"Sanofi",150,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100645036","phase-2-thymosin-1-for-recurrent-implantation-failure-100645036","NCT07675980","Thymosin-α1 for Recurrent Implantation Failure","Thymosin-α1 for Recurrent Implantation Failure Following Transfer of PGT-a Tested Embryo: A Randomized, Double-Blind, Placebo-Controlled Trial","Thy-α1 for RIF","Inclusion Criteria:\n\n1. -Women 18-40 years\n2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos\n3. \\- Normal parental karyotypes\n4. \\- Normal uterine cavity on imaging\n5. \\- Negative antiphospholipid panel\n6. \\- Thyroid and prolactin controlled within local reference standards\n\nExclusion Criteria:\n\n1. Identified\u002Fcorrectable non-immune cause of RPL (chromosomal, anatomic, endocrine)\n2. \\- Active malignancy\n3. -Active infection\n4. \\- Uncontrolled systemic disease\n5. \\- Current systemic immunosuppression","FEMALE","18 Years","40 Years",{"count":100,"type":23},136,[102,26],"PHASE2","Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF\u002FICSI cycles.",[105],"Recurrent Implantation Faliure",[107,108,109,110],"Thymosin","recurrent implantation failure","Thymosin alpha","PGT-a tested embryos","2026-06-29",{"date":113,"type":34},"2026-06-30",{"date":115,"type":34},"2026-02-11",{"date":117,"type":23},"2027-06",{"name":119,"class":120},"Fakih IVF Fertility Center","OTHER",1,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":18,"minAge":97,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":24,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":121},"100644864","cooking-classes-as-a-family-based-intervention-for-weight-reduction-effects-on-dietary-quality-and-weight-management-in-abu-dhabi-united-arab-emirates-100644864","NCT07675148","Cooking Classes as a Family-based Intervention for Weight Reduction: Effects on Dietary Quality and Weight Management in Abu Dhabi (United Arab Emirates)","Inclusion Criteria:\n\n* Emirati\n* Based in Abu Dhabi\n* Home cooked meals prepared by full-time home cooks who are certified in the ICCA Culinary Medicine course (post 4 weeks cooking training)\n* Certified home cooks are residing with participant during the training and intervention\n* Aged between 18 years and 60 years\n* BMI between 28-40 kg\u002Fm2\n* Participant and cooks being able to provide informed consent\n\nExclusion Criteria:\n\n* Body weight exceeding 220 kilograms at the time of recruitment\n* Undergoing treatment for serious illnesses (active cancer), planned for surgery, interventional management, and immunomodulation\n* Undergone surgery within 3 months prior to study recruitment, including bariatric surgery\n* Enrolled in other lifestyle intervention programs",true,"60 Years",{"count":131,"type":23},500,[133],"NA","The goal of this quasi-experimental interventional study is to learn if healthy cooking classes for home cooks can improve weight management and dietary quality among Emirati adults with overweight or obesity living in Abu Dhabi. The main questions it aims to answer are:\n\n* Does participation in the culinary medicine program reduce body weight over time?\n* Does the intervention improve diet quality and increase compliance with healthy home-cooked meals?\n* Does the intervention improve health measures such as waist circumference, body fat percentage, blood pressure, and heart rate?\n* What are the experiences and satisfaction levels of participating family members and trained home cooks?\n\nParticipants will:\n\n* Enroll in a 3-month family-based nutrition intervention program\n* Receive meals prepared by home cooks trained in culinary medicine through the ICCA program\n* Complete assessments before the intervention, during the intervention, and 3 months after completion\n* Undergo measurements including weight, waist circumference, body fat percentage, blood pressure, and heart rate\n* Complete questionnaires about diet quality, meal habits, and overall program experience",[136,137],"Obesity & Overweight","Culinary Medicine",{"date":113,"type":34},{"date":140,"type":34},"2025-10-08",{"date":142,"type":23},"2026-10-31",{"name":144,"class":120},"Institute for Healthier Living Abu Dhabi",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100473302","phase-1-a-study-of-ep0031-lunbotinib-in-patients-with-advanced-ret-altered-malignancies-100473302","NCT05443126","A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","A Modular, Open-label, Phase I\u002FII Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies","Inclusion Criteria:\n\nApplicable to all participants:\n\n1. Must be ≥18 years of age, with documented RET-altered NSCLC\n2. Participants should be well informed and consented about alternative treatment options including approved RET-targeted therapies\n3. ECOG performance status of 0 or 1 and life expectancy \\>3 months at screening\n4. Ability to understand and provide written informed consent and able to participate in all required evaluations and procedures\n5. Measurable disease defined by RECIST v1.1\n6. Must have locally advanced or metastatic NSCLC with RET fusion who are eligible to receive platinum-based doublet chemotherapy.\n7. First line patients: Must not have received a Selective RET inhibitor or chemotherapy. Prior adjuvant and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiation\u002Fchemoradiation with or without regimens including immunotherapy, biologic therapy, investigational agents, are permitted as long as treatment was completed at least 12 months prior. Palliative radiotherapy for symptom management (eg, bone metastases) is permitted up to 2 weeks prior to treatment start.\n\nExclusion Criteria:\n\nParticipants with any of the following will not be included in the study:\n\n1. Any known major driver gene alterations other than RET.\n2. Spinal cord compression or brain metastases. Patients with stable brain metastases can be enrolled.\n3. Active infection requiring systemic antibiotic, antifungal, or antiviral medication\n4. Severe or uncontrolled medical condition or psychiatric condition\n5. Chronic glomerulonephritis or renal transplant\n6. Participants with active hepatitis B infection or active hepatitis C\n7. Participants with active HIV infection. Patients living with HIV may be eligible if they have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic infections in the past 12 months\n8. Receipt of any strong inhibitor or inducer of CYP3A4\n9. Impaired hepatic or renal function, inadequate bone marrow reserve or organ function\n10. Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG or any factor that increases the risk of QTc prolongation or of arrhythmic events , or congestive heart failure Grade III-IV according to the New York Heart Association, myocardial infarction, or unstable angina within the previous 6 months\n11. Uncontrolled hypertension\n12. Corneal ulceration or untreated keratitis at screening",{"count":153,"type":23},265,[155,102],"PHASE1","The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.",[158],"NSCLC",[160,158,161,162,163,164,165],"selective RET-inhibitor","RET","EP0031","A400","Chemotherapy","lunbotinib",{"date":31,"type":34},{"date":168,"type":34},"2022-09-30",{"date":170,"type":23},"2028-03",{"name":172,"class":41},"Ellipses Pharma",52,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":182,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":121},"100645392","an-investigation-of-the-effect-of-vitamin-d-level-during-frozen-embryo-transfer-fet-in-ivf-and-pregnancy-outcomes-100645392","NCT07681115","An Investigation of the Effect of Vitamin D Level During Frozen Embryo Transfer (FET) in IVF and Pregnancy Outcomes","Vitamin D Levels and Pregnancy Outcomes Following Frozen Embryo Transfer (FET) in the UAE","VitD in FET","Inclusion:\n\n* Women undergoing frozen embryo transfer (FET) at Fakih IVF.\n* Age between 18 and 40 years.\n* Body mass index (BMI) between 18 and 40 kg\u002Fm².\n* Patients who had serum vitamin D levels assessed within three months prior to FET\n* Supplementation with Vitamin D if deficient \\\u003C 30 ng\u002FmL (75 nmol\u002FL).\n\nExclusion:\n\n* Age below 18 years or above 40 years.\n* BMI below 18 kg\u002Fm² or above 40 kg\u002Fm².\n* Patients who did not have vitamin D levels measured within three months prior to FET.\n* Patients who were found to have low vitamin D levels but did not receive supplementation.\n* Patients with recurrent implantation failure (RIF).\n* Patients with known uterine factors affecting implantation (e.g., congenital uterine anomalies, intrauterine adhesions, submucosal fibroids).\n* Patients with significant medical comorbidities that may affect pregnancy outcomes.",{"count":183,"type":23},126,"Vitamin D is best known for keeping our bones healthy, but growing research suggests it may also play a role in fertility. Many IVF clinics now routinely check vitamin D levels and prescribe supplements before treatment, but the science is still unclear on whether this actually improves the chances of pregnancy.\n\nOur study, based in the UAE, aims to find out whether a woman's vitamin D level on the day of her frozen embryo transfer (FET) makes a difference to whether she becomes pregnant and delivers a baby. The UAE is an ideal setting for this research, as vitamin D deficiency is particularly common in the region. The findings could shape how fertility clinics screen and treat women seeking fertility treatment in the future.",[186,187],"Vitamin D Insufficiency","In Vitro Fertilization and Embryo Transfer",[189,190],"frozen embryo transfer cycle","Vitamin D","2026-06-26",{"date":33,"type":34},{"date":194,"type":34},"2026-06-01",{"date":196,"type":23},"2027-08",{"name":119,"class":120},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":24,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":218,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100644587","feasibility-and-effectiveness-of-an-ai-powered-carbohydrate-counting-educational-platform-to-support-parents-of-children-with-type-1-diabetes-100644587","NCT07671053","Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes","Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes: A Multicentre Randomized Controlled Trial","CARB-AI","Inclusion Criteria:\n\n* Primary responsibility for carbohydrate counting and insulin dosing decisions for the child\n* English-speaking\n* Access to a smartphone (iOS or Android) with internet connectivity\n* Willing and able to provide informed consent and complete study procedures\n* Diagnosis of type 1 diabetes for at least 1 month\n* Receiving intensive insulin therapy (multiple daily injections or insulin pump)\n* Using carbohydrate counting for insulin dosing\n\nExclusion Criteria:\n\n* Child has significant developmental delay or a medical condition that substantially alters nutritional requirements or carbohydrate metabolism (e.g., celiac disease, cystic fibrosis)\n* Parent or caregiver has significant cognitive impairment that would preclude participation\n* Family plans to relocate from the study area during the study period\n* Participation in another diabetes intervention study",{"count":207,"type":23},80,[133],"The goal of this clinical trial is to learn whether an AI-powered carbohydrate counting educational platform can help parents of children with type 1 diabetes improve their carbohydrate counting skills and diabetes management. The study will include parents or primary caregivers of children aged 2-12 years with type 1 diabetes.\n\nThe main questions it aims to answer are:\n\n* Is the AI-powered educational platform feasible, acceptable, and easy for parents to use?\n* Can the platform improve carbohydrate counting accuracy, parental confidence in diabetes management, and diabetes outcomes compared with usual education alone?\n\nResearchers will compare parents who receive access to the AI-powered carbohydrate counting educational platform plus usual diabetes education with parents who receive usual diabetes education alone to see whether the AI-supported approach provides additional benefits.\n\nParticipants will:\n\n* Complete baseline assessments, including questionnaires and a carbohydrate counting test.\n* Be randomly assigned to either the AI-supported education group or the usual education group.\n* Use the assigned educational resources for 12 weeks.\n* Complete a follow-up assessment at 6 weeks and a final assessment at 12 weeks.\n* Provide information about their child's diabetes management, including HbA1c and glucose monitoring data.\n* Complete questionnaires about confidence, usability, and satisfaction with the educational support they receive.\n\nThe AI platform is designed to provide educational support only and does not replace medical advice, insulin dosing decisions, or routine diabetes care provided by healthcare professionals.",[211],"Type 1 Diabetes Mellitus",[213,214,215,216,217],"Type 1 Diabetes","Carbohydrate Counting","Artificial Intelligence","AI-Powered Education","Digital Health","NOT_YET_RECRUITING",{"date":113,"type":34},{"date":221,"type":23},"2026-09-01",{"date":223,"type":23},"2027-12-31",{"name":225,"class":120},"Sultan Qaboos University",3,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":20,"enrollmentInfo":236,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100598310","study-of-clinical-and-patient-reported-outcomes-in-adults-with-moderate-to-severe-copd-treated-with-breztritrixeo-100598310","NCT07069829","Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri\u002FTrixeo","Real-world, International, Multicentre, Non-interventional, Prospective Cohort to Assess Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri\u002FTrixeo in Routine Care Settings","iCHOROS","Inclusion Criteria:\n\nThe study will include patients who were prescribed BGF, but not yet initiated, according to the label (SmPC) and local market reimbursement criteria. Patients will only be included in the study if they meet the following inclusion criteria:\n\n1. Patients diagnosed with COPD, at least 12 months before baseline, as assessed per physician's routine practice or as documented in the patient's chart.\n2. Male or female patients aged over 30 years and under 80 years at the time of enrolment.\n3. Patients providing a written Informed Consent\\* prior to inclusion to the study.\n\n   \\*Prescription of BGF should be prior to the signed informed consent and the decision to prescribe this therapy is clearly separated from the physician's decision to include the patient in the current study.\n4. Patients able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will not be eligible to participate in the study:\n\n1. Patients with COPD due to documented α-1 antitrypsin deficiency.\n2. Patients with recent (≤3 months) major cardiac or pulmonary events that required hospitalization (e.g., myocardial infarction, pulmonary embolism).\n3. Patients previously treated with triple fixed-dose combination therapies 12 months before the screening visit or treated with Multiple Inhaled Triple Therapy (MITT) within the last 3 months before the screening visit.\n4. Patients hospitalized due to COPD exacerbations within the last 30 days prior to enrolment.\n5. Currently pregnant (or intending to become pregnant), breastfeeding, or lactating women.\n6. Patients with a current diagnosis of asthma, active tuberculosis, lung cancer or lung metastasis, significant bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases, or other active clinically significant pulmonary diseases.\n7. Patients currently participating in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study or participation in any interventional trial in the last 30 days prior to enrolment.\n8. Patients with respiratory tract infection (including COVID-19 infection) ) that has not resolved ≤30 days prior to BGF MDI initiation and those exhibiting persistent long-COVID symptoms are excluded from the study.","30 Years",{"count":237,"type":23},1400,"Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI\u002FTRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life.\n\nThe iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \\& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations",[240],"Chronic Obstructive Pulmonary Disease",[242,243,244,245],"COPD","Moderate to Severe Chronic Obstructive Pulmonary Disease","Severe Exacerbations","BGF - Budesonide\u002FGlycopyrrolate\u002FFormoterol Fumarate",{"date":111,"type":34},{"date":248,"type":34},"2025-12-15",{"date":250,"type":23},"2027-09-30",{"name":252,"class":41},"AstraZeneca",36,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100548526","phase-3-pembrolizumab-with-or-without-maintenance-sacituzumab-tirumotecan-sac-tmt-mk-2870-in-metastatic-squamous-non-small-cell-lung-cancer-nsclc-mk-2870-023-100548526","NCT06422143","Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","Phase 3 Study of Pembrolizumab in Combination With Carboplatin\u002FTaxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \\[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\\]\n* Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator\u002Fradiology\n* Has life expectancy ≥3 months\n* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation\n* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)\n* Has adequate organ function\n* For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization\n* For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit\n* For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade ≤2 fatigue, Grade ≤2 peripheral neuropathy, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered\n* For Maintenance only (prior to randomization): has not experienced a pneumonitis\u002Finterstitial lung disease (ILD) event during the study-specified induction\n\nExclusion Criteria:\n\n* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* History of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention\n* HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and\u002For radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC\n* Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC\n* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)\n* Received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications\n* Received prior treatment with a topoisomerase I inhibitor-containing ADC\n* Is currently receiving a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks)\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known central nervous system (CNS) metastases\u002Fcarcinomatous meningitis\n* Severe hypersensitivity (≥Grade 3) to study intervention and\u002For any of its excipients or to another biologic therapy\n* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \\[eg, thyroxine, insulin, or physiologic corticosteroid\\] is allowed)\n* Has a history of (noninfectious)pneumonitis\u002FILD that required steroids, has current pneumonitis\u002FILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening\n* Active infection requiring systemic therapy\n* History of allogeneic tissue\u002Fsolid organ transplant",{"count":262,"type":23},851,[26],"This is a phase 3 study of pembrolizumab in combination with carboplatin\u002Ftaxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).",[266,158],"Non-small Cell Lung Cancer",{"date":111,"type":34},{"date":269,"type":34},"2024-06-10",{"date":271,"type":23},"2031-02-12",{"name":273,"class":41},"Merck Sharp & Dohme LLC",212,{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":128,"sex":18,"minAge":282,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":292,"overallStatus":218,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":121},"100645188","influence-of-re-evaluation-timing-after-phase-i-periodontal-therapy-on-clinical-and-periodontal-outcomes-100645188","NCT07678125","Influence of Re-evaluation Timing After Phase I Periodontal Therapy on Clinical and Periodontal Outcomes.","Influence of Re-evaluation Timing After Phase I Periodontal Therapy on Clinical and Periodontal Outcomes. A Split-mouth Study","Inclusion Criteria:\n\n* Patients above 18 yrs\n* Patients that are systemically healthy\n* Patients diagnosed as Stage III or Stage IV Periodontitis\n* Patients willing to participate in the study and provide informed consent.\n* Patients with no recent history of periodontal therapy\n* Presence of ≥20 natural teeth\n\nExclusion criteria:\n\n* Patients with a history of medical conditions or diseases that may affect healing or periodontal tissues.\n* Patients who are pregnant\n* Patients on Drugs\u002Fmedication that may affect the periodontal tissue\n* Smokers or tobacco users\n* Patients that cannot complete the 12-week follow-up period","21 Years","70 Years",{"count":285,"type":23},24,[133],"Periodontal disease remains a highly prevalent chronic inflammatory condition affecting the supporting structures of the teeth and is a leading cause of tooth loss worldwide. Contemporary periodontal therapy is structured into sequential phases, with non-surgical periodontal therapy (NSPT) forming the cornerstone of initial management. Following this phase, re-evaluation of periodontal status is critical to determine treatment outcomes and guide further intervention, including surgical therapy if required (1,2).\n\nRe-evaluation phase serves multiple purposes: it allows assessment of tissue response to therapy, measurement of reductions in probing pocket depth (PPD), gains in clinical attachment level (CAL), and evaluation of patient compliance with oral hygiene practices. It also aids in identifying residual pockets or persistent inflammation that may necessitate additional treatment (1,3). Despite its clinical importance, the optimal timing of re-evaluation remains inconsistently defined in the literature (1). Generally, current literature utilizes a timing frame from 1-3 months; up to 9 months (3,4). Current clinical guidelines, including those from the European Federation of Periodontology (EFP), generally recommend assessing whether the end points have been achieved; no periodontal pockets ≥ 5mm with bleeding on probing and no pocket ≥ 6mm (5).\n\nEmerging evidence suggests that certain clinical improvements, particularly reductions in inflammation and bleeding on probing (BOP), may occur as early as 4 weeks following therapy, raising questions about whether earlier re-evaluation could be clinically beneficial (2,3). Early reassessment may allow for more timely identification of non-responding sites, enabling prompt intervention and potentially improving overall treatment outcomes. Conversely, other studies indicate that full periodontal healing and maturation of tissues may require longer periods, supporting delayed re-evaluation intervals (1,2,3).\n\nFurthermore, patient-related factors such as systemic health, smoking status, and baseline disease severity may influence healing dynamics and thus the appropriate timing for reassessment (1). The heterogeneity of these factors highlights the potential need for a more individualized approach to re-evaluation rather than a fixed universal timeframe.\n\nDespite these considerations, there is a notable lack of high-quality comparative studies directly evaluating short-term versus conventional re-evaluation intervals following NSPT. Most available studies focus on treatment outcomes rather than the timing of reassessment itself. This creates a significant gap in the literature, particularly regarding whether earlier re-evaluation could enhance clinical decision-making, improve patient outcomes, or optimize resource utilization in clinical practice.\n\nIn addition, with increasing emphasis on minimally invasive and patient-centered care, there is a growing need to refine periodontal treatment protocols to ensure efficiency without compromising effectiveness. Determining the optimal timing of re-evaluation could contribute to improved treatment planning, reduced disease progression, and enhanced long-term periodontal stability.\n\nTherefore, this study aims to address this gap by investigating the effectiveness and clinical implications of shorter re-evaluation intervals following periodontal therapy, compared to conventional timeframes.",[289,290,291],"Periodontal Diseases","Periodontitis (Stage 3)","Subgingival Debridement",[293],"periodontal disease","2026-06-25",{"date":31,"type":34},{"date":194,"type":23},{"date":298,"type":23},"2027-02-15",{"name":300,"class":120},"Gulf Medical University",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":322},"100583779","phase-3-study-of-plozasiran-in-adults-with-severe-hypertriglyceridemia-at-risk-of-acute-pancreatitis-100583779","NCT06880770","Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis","Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)","SHASTA-5","Inclusion Criteria:\n\n* Males, or nonpregnant (who do not plan to become pregnant) nonlactating females\n* Established diagnosis of SHTG and prior documented evidence of fasting TG levels of ≥ 880 mg\u002FdL (≥ 10 mmol\u002FL)\n* Documented evidence of at least 1 prior AP event not attributed to other etiologies occurring within the last 60 months prior to Screening.\n* Fasting low-density lipoprotein cholesterol (LDL-C) ≤ 130 mg\u002FdL (≤ 3.37 mmol\u002FL) at Screening\n* Screening hemoglobin A1c (HbA1c) ≤ 9.5%\n* Willing to follow diet counseling and maintain a stable low-fat diet\n* Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant, or a treatment failure as determined by the Investigator)\n\nExclusion Criteria:\n\n* Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and\u002For triglycerides within 365 days before Day 1, except inclisiran.\n* Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives lives before day 1. Whichever is longer.\n* AP ≤ 4 weeks prior to Randomization\u002FDay 1\n* Body mass index (BMI) \\> 45 kg\u002Fm\\^2\n* Any planned bariatric surgery or similar procedures to induce weight lost starting at consent through End of Study (EOS)\n* Planned coronary intervention (e.g. stent placement or heart bypass) during the study\n* History of arterial revascularization within 16 weeks of Screening\n* History of acute coronary syndrome event within 24 weeks of Screening\n* Recent atherosclerotic cardiovascular disease (ASCVD) event within 24 weeks of Screening\n* Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days of Screening. Individuals with stable well-controlled atrial arrhythmia will be allowed to participate in the study\n* History of pacemaker or automatic implantable cardioverter defibrillators implant within 30 days before Screening\n* New York Heart Association Class III-IV heart failure or last known ejection fraction of \\\u003C 30%\n* Current diagnosis of nephrotic syndrome\n* Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) \\\u003C 20 mL\u002Fmin\u002F1.73 m\\^2\n* Liver disease defined as cirrhosis or Child-Pugh Class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5× Upper Limit of Normal (ULN) at Screening\n\nNote: Additional Inclusion\u002FExclusion Criteria may apply per protocol",{"count":310,"type":23},288,[26],"This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.",[314],"Severe Hypertriglyceridemia",{"date":191,"type":34},{"date":317,"type":34},"2025-04-24",{"date":319,"type":23},"2029-06",{"name":321,"class":41},"Arrowhead Pharmaceuticals",95,{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":128,"sex":18,"minAge":282,"maxAge":283,"enrollmentInfo":330,"targetDuration":4,"studyType":24,"phases":332,"briefSummary":333,"conditions":334,"keywords":339,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":121},"100644844","evaluation-of-lateral-sinus-floor-elevation-using-xenograft-versus-l-prf-block-combined-with-xenograft-100644844","NCT07677007","Evaluation of Lateral Sinus Floor Elevation Using Xenograft Versus L-PRF Block Combined With Xenograft","Evaluation of Lateral Sinus Floor Elevation Using Xenograft Versus L-PRF Block Combined With Xenograft: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults aged 21 years or older.\n* Partially edentulous posterior maxilla requiring implant-supported rehabilitation.\n* Residual bone height between 2 and 5 mm measured by CBCT.\n* Good oral hygiene and compliance with maintenance visits.\n* ASA I or II patients.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases.\n* Smoking more than 10 cigarettes\u002Fday.\n* Active sinus pathology or chronic sinusitis.\n* Previous sinus augmentation surgery.\n* Pregnancy or lactation.\n* Bisphosphonate therapy.\n* Immunocompromised patients.\n* History of head and neck radiotherapy",{"count":331,"type":23},30,[133],"Rehabilitation of the posterior maxilla with dental implants is frequently complicated by insufficient residual bone height resulting from alveolar ridge resorption and maxillary sinus pneumatization. Lateral sinus floor elevation has become a predictable and widely accepted procedure for increasing bone volume and enabling implant placement in severely atrophic posterior maxillary sites. The long-term success of this procedure is largely dependent on the grafting material used to maintain space beneath the elevated Schneiderian membrane and promote new bone formation.\n\nDeproteinized bovine bone mineral (DBBM), commonly known as xenograft, remains the most extensively documented grafting material for sinus augmentation due to its osteoconductive properties, volumetric stability, and favorable long-term clinical outcomes. However, xenografts are characterized by slow remodeling and prolonged persistence of residual graft particles, which may delay replacement by vital bone. Consequently, strategies to enhance the biological activity of xenografts and accelerate bone regeneration have become an area of considerable research interest.\n\nLeukocyte- and platelet-rich fibrin (L-PRF) is a second-generation autologous platelet concentrate containing a fibrin matrix enriched with platelets, leukocytes, cytokines, and growth factors including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-β (TGF-β). These biological mediators may enhance angiogenesis, accelerate wound healing, stimulate osteoblast proliferation, and improve bone regeneration.\n\nSeveral studies have demonstrated promising outcomes when L-PRF is used in sinus augmentation procedures. Mazor et al. reported successful bone formation and implant placement following sinus augmentation using PRF as the sole grafting material after six months of healing. Histological analysis demonstrated the formation of newly regenerated vital bone within the augmented sinus compartment.\n\nMore recently, Cortellini et al. conducted a randomized controlled trial comparing L-PRF block and DBBM in lateral sinus floor elevation. Although both techniques allowed successful implant placement after six months, differences in volumetric stability and graft remodeling were observed. The authors suggested that L-PRF-containing grafts may represent a biologically active alternative capable of enhancing healing while maintaining sufficient bone volume for implant placement.\n\nPichotano et al. further demonstrated that combining L-PRF with DBBM accelerated bone maturation and facilitated earlier implant placement when compared with xenograft alone. Histomorphometric findings revealed greater percentages of newly formed bone and reduced healing times in the L-PRF group.\n\nDespite these promising findings, the available evidence remains limited, and there is no clear consensus regarding whether the addition of L-PRF to xenografts results in clinically significant improvements in bone regeneration, volumetric maintenance, and implant site development. Therefore, a randomized controlled clinical trial comparing xenograft alone versus L-PRF block combined with xenograft during lateral sinus floor elevation is warranted.",[335,336,337,338],"Sinus Floor Augmentation","Maxillary Sinus Floor Elevation","Sinus Lift","Xenograft",[340],"maxillary sinus","2026-06-24",{"date":113,"type":34},{"date":344,"type":34},"2026-01-01",{"date":346,"type":23},"2027-02-01",{"name":300,"class":120},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":73,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100615299","this-study-is-a-non-interventional-disease-registry-of-adolescent-and-adult-patients-with-atopic-dermatitis-who-initiate-or-switch-any-systemic-treatment-100615299","NCT07290803","This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","Atopic Dermatitis Disease Registry of Adult and Adolescent Patients Initiating or Switching Systemic Treatments","ARMADA-AD","Inclusion Criteria:\n\n* Patients aged more than or equal to (≥) 12 years at the time of consent.\n* Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20.\n* Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)\n* Signed informed consent for registry participation by the patient or parent\u002Flegal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up.\n\nExclusion Criteria:\n\n* Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care.\n* Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":357,"type":23},1000,"The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.\n\nThe study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.",[360],"Atopic Dermatitis",{"date":294,"type":34},{"date":363,"type":34},"2025-11-17",{"date":365,"type":23},"2034-01-30",{"name":86,"class":41},59,{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":24,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":393},"100512446","phase-3-an-adjuvant-endocrine-based-therapy-study-of-camizestrant-azd9833-in-erher2--early-breast-cancer-cambria-2-100512446","NCT05952557","An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+\u002FHER2- Early Breast Cancer (CAMBRIA-2)","CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+\u002FHER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease","CAMBRIA-2","Inclusion Criteria:\n\n* Women and Men; ≥18 years at the time of screening (or per national guidelines)\n* Histologically confirmed ER+\u002FHER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the protocol.\n* Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy.\n* Patients must be randomised within 12 months of definitive breast surgery.\n* Patients may have received up to 12 weeks of endocrine therapy prior to randomisation.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\n* Adequate organ and bone marrow function\n\nExclusion Criteria:\n\n* Inoperable locally advanced or metastatic breast cancer\n* Pathological complete response following treatment with neoadjuvant therapy\n* History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation\n* Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance \"\n* Known LVEF \\\u003C50% with heart failure NYHA Grade ≥2.\n* Mean resting QTcF interval \\> 480 ms at screening\n* Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions\n* Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab)\n* Previous treatment with camizestrant, investigational SERDs\u002Finvestigational ER targeting agents, or fulvestrant\n* Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding.\n* Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-\u002Fperi-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist.","130 Years",{"count":378,"type":23},5500,[26],"This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+\u002FHER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.",[382],"Breast Cancer, Early Breast Cancer",[384,385,386],"ER+","HER2-","breast cancer",{"date":294,"type":34},{"date":389,"type":34},"2023-10-05",{"date":391,"type":23},"2037-05-06",{"name":252,"class":41},798,{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":24,"phases":403,"briefSummary":404,"conditions":405,"keywords":424,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":463},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.",{"count":131,"type":23},[133],"This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423],"Retinal Disease","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[425,426,427,428,429,430,431,432,433,406,422,434,435,436,437,438,439,440,441,442,408,409,443,444,445,421,413,412,410,446,447,448,449,450,451,452,453,454,415,416,455,423],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss",{"date":111,"type":34},{"date":458,"type":34},"2016-01",{"date":460,"type":23},"2028-07-31",{"name":462,"class":41},"MD Stem Cells",4,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":474,"conditions":475,"keywords":502,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":226},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":131,"type":23},[133],"This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[503,504,480,481,505,506,494,507,485,500,497,508],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":191,"type":34},{"date":511,"type":34},"2016-06",{"date":460,"type":23},{"name":462,"class":41},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":128,"sex":18,"minAge":97,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":121},"100594040","virtual-reality-for-mindfulness-and-anxiety-reduction-in-fertility-procedures-100594040","NCT07014267","Virtual Reality for Mindfulness and Anxiety Reduction in Fertility Procedures","Inclusion Criteria:\n\n* Patients aged 18-50.\n* Scheduled for fertility-related surgical procedures.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* History of motion sickness or VR-related discomfort.\n* Cognitive or psychological conditions affecting participation.\n* Procedures requiring emergency intervention.","50 Years",{"count":131,"type":23},[133],"This study aims to evaluate the effectiveness of a Virtual Reality (VR)-based mindfulness and meditation intervention in reducing anxiety among patients undergoing fertility-related surgical procedures. Anxiety is a common challenge in fertility treatments, often leading to emotional distress and increased pain perception. By incorporating a non-invasive VR intervention, the investigators seek to improve patient experience, minimize preoperative anxiety, and potentially reduce postoperative discomfort and recovery times. This randomized controlled trial (RCT) will compare standard care with a VR intervention in a clinical setting, measuring key outcomes such as anxiety levels, pain perception, recovery duration, and overall patient satisfaction. The findings may contribute to more patient centered fertility care, offering an innovative, scalable, and cost-effective approach to anxiety management in reproductive medicine.",[525,526],"Virtual Reality","Patient Experience",[528,529,530,531,532],"anxiety","stress","pain perception","recovery duration","virtual reality","2026-06-22",{"date":294,"type":34},{"date":536,"type":34},"2025-07-10",{"date":538,"type":23},"2026-12-31",{"name":540,"class":120},"ART Fertility Clinics LLC",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":128,"sex":96,"minAge":547,"maxAge":548,"enrollmentInfo":549,"targetDuration":551,"studyType":53,"phases":4,"briefSummary":552,"conditions":553,"keywords":558,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":570},"100586047","whole-brain-dynamics-in-the-natural-menstrual-cycle-vs-an-ovarian-stimulated-cycle-impact-of-hormonal-fluctuations-on-healthy-women-undergoing-ovarian-stimulation-100586047","NCT06910293","Whole-Brain Dynamics in the Natural Menstrual Cycle vs. an Ovarian Stimulated Cycle: Impact of Hormonal Fluctuations on Healthy Women Undergoing Ovarian Stimulation","Inclusion Criteria:\n\n* Age group: 25 - 35 years old\n* BMI: 20 - 30\n* Anti-Mullerian Hormone (AMH): 1.3 - 5.9 ng\u002Fml\n* Regular Menstrual Cycle: 26-35 days\n* In case of previous use of hormonal contraception: wash-out period of 3 month\n* Meet standard safety and eligibility criteria for MRI scanning, including the absence of contraindications such as metallic implants, claustrophobia, or other medical conditions that preclude MRI\n\nExclusion Criteria:\n\n* History of ovarian surgery\n* Pathology of the ovaries\n* Mental health disorders\n* Use of medication influencing brain function\n* Ongoing use of hormonal contraception (this would include OCP, but also patches and Mirena containing IUD)","25 Years","35 Years",{"count":550,"type":23},15,"8 Weeks","The investigators aim is to investigate the brain's dynamic complexity across three phases of an ovarian stimulation cycle (basal, pre-OPU, mid-luteal), to observe the impact of externally administered hormones, and compare it with the corresponding phases of a natural menstrual cycle (early follicular, pre-ovulatory, mid-luteal) in the same woman. Brain activity patterns will be examined using resting-state fMRI in a sample of young, healthy, naturally cycling women.",[554,555,556,557],"Neural Activity","Brain Function","Neurodynamics","Brain Connectivity",[559,560,561,562,563],"Menstrual Cycle","Ovarian Stimulated Cycle","Endocrine Profile","neural activity","neurodynamics",{"date":565,"type":34},"2026-06-23",{"date":567,"type":34},"2025-04-07",{"date":538,"type":23},{"name":540,"class":120},2,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":128,"sex":96,"minAge":97,"maxAge":577,"enrollmentInfo":578,"targetDuration":580,"studyType":53,"phases":4,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":588,"locationsCount":121},"100580590","follicular-volume-at-the-time-of-final-oocyte-maturation-in-poor-responders-and-its-correlation-with-oocyte-maturity-100580590","NCT06839274","Follicular Volume at the Time of Final Oocyte Maturation in Poor Responders, and Its Correlation With Oocyte Maturity","Inclusion Criteria:\n\n* Reproductive age group: 18 -48\n* undergoing ovarian stimulation for oocyte vetrification\n* undergoing IVF\u002F ICSI with PGT-A \u002F PGT-M \u002F PGT- Sr\n* less than or equal to 3 AFC on initiation of stimulation\n* follicular phase stimulation\n\nExclusion Criteria:\n\n* surgically retrieved sperm","48 Years",{"count":579,"type":23},100,"30 Months","Women with a severely diminished ovarian reserve and monofollicular growth are at a higher risk of premature ovulation as well as poor quality oocytes. Our group showed previously that women with severely diminished ovarian reserve benefit from receiving the final oocyte maturation at smaller follicle sizes in terms of reducing the risk of premature ovulation and finding mature oocytes even out of small size follicles.\n\nAdding the measurement of the follicular volume at the time of final oocyte maturation might provide more information on the proper timing of trigger administration compared to the follicular size alone, hormonal profile as well as previous stimulation attempts. Setting a cutoff value of follicular volume for trigger might help to avoid premature ovulation and possibly increase the chances of ending up with a euploid embryo.",[583],"OVARIAN STIMULATION",{"date":294,"type":34},{"date":586,"type":34},"2025-03-27",{"date":538,"type":23},{"name":540,"class":120},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":128,"sex":96,"minAge":97,"maxAge":597,"enrollmentInfo":598,"targetDuration":599,"studyType":53,"phases":4,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":121},"100560114","serum-fsh-monitoring-for-identification-of-an-optimal-range-during-ovarian-stimulation-100560114","NCT06572930","Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation","Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders","FSH","Inclusion Criteria:\n\n* regular 21 - 35 days cycles\n* BMI between 19 - 30 kg\u002Fm2\n* serum AMH level between 1.5 to 3 ng\u002Fml\n* a total antral follicle count between 10 to 24\n* endogenous early follicular phase serum FSH level \\\u003C10 IU\u002FL\n* normal glomerular filtration rate\n\nExclusion Criteria:\n\n* hypogonadotropic hypogonadism\n* history of ovarian surgery\n* permanent ovarian cysts of any form\n* older than 39 years\n* abnormal thyroid stimulating hormone (TSH)\n* renal disease\n* elevated prolactin levels\n* intake of oral contraceptives 3 months before stimulation start and estradiol pretreatment will be excluded","39 Years",{"count":87,"type":23},"1 Year","This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.",[602],"Ovarian Stimulation",[604,605,606,607],"ovarian response","stimulation protocols","stimulation monitoring","follicular stimulating hormone",{"date":294,"type":34},{"date":610,"type":34},"2024-12-16",{"date":612,"type":23},"2026-12-01",{"name":540,"class":120},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":128,"sex":96,"minAge":97,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":24,"phases":625,"briefSummary":626,"conditions":627,"keywords":634,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":649,"locationsCount":121},"100528791","hyaluronan-enriched-medium-and-euploid-blastocyst-transfers-100528791","NCT06165367","Hyaluronan-enriched Medium and Euploid Blastocyst Transfers","Impact of Hyaluronan-enriched Medium on Pregnancy Outcomes Following Euploid Blastocyst Transfers","GluePloid","Inclusion Criteria:\n\n* All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.\n* Rank of randomization based on embryo quality.\n* Only hormonal replacement theraphy (HRT) cycle regimen.\n* Women aged 18 years to 46 years.\n* Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.\n* All sperm samples.\n* BMI between 18 and 35.\n\nExclusion Criteria:\n\n* FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).\n* FET cycles with mosaic \u002F aneuploid blastocysts.\n* FET cycles with unknown outcome.\n* FET cycles with Day 6 or Day 7 biopsied blastocysts.\n* FET with patients' endometrium preparation with treatments other than HRT.\n* FET where PGT-A was performed for gender selection.","46 Years",{"count":624,"type":23},783,[133],"It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos. In order to investigate the impact of this hyaluronan-enriched on pregnancy outcomes, it is essential to evaluate its efficacy on euploid-only embryo transfers. The aim of the present study is to evaluate whether a short period of exposure of euploid blastocysts to EmbryoGlue prior to and during transfer positively impact on pregnancy outcomes of frozen embryo transfer (FET) cycles.",[628,629,630,631,632,633],"Infertility","Implantation Rate","Clinical Pregnancy Rate","Live Birth Rate","Blastocysts","FET",[635,636,637,638,639,640,641,642,643,644],"HRT","PGT-A","Next-generation sequencing (NGS)","Miscarriage rate","single embryo transfer (SET)","EmbryoGlue","BMI","Embryo quality","Hyaluronan-enriched medium","Transfer medium",{"date":294,"type":34},{"date":647,"type":34},"2024-01-15",{"date":538,"type":23},{"name":540,"class":120},{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":96,"minAge":4,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":659,"conditions":660,"keywords":665,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":672,"locationsCount":226},"100513753","is-decreased-ovarian-reserve-related-to-an-increased-number-of-previous-early-miscarriages-100513753","NCT05969574","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages? A Prospective Observational Study","Inclusion Criteria:\n\n1\\. All participants with at least 1 previous pregnancy, who are assessed in one of our clinics (ART Fertility Clinics Abu Dhabi, Al Ain, Dubai)\n\nExclusion Criteria:\n\n1. Severe male factor (azoospermia, cryptozoospermia, severe oligoasthenoteratozoospermia (OAT))\n2. Severe Endometriosis and adenomyosis based on positive anamnesis or ultrasound performed in our center during the first consultation\n3. Uterine abnormalities (e.g. fibroids, different degrees of uterine septum), diagnosed by ultrasound\n4. History of ovarian surgery, chemotherapy, or radiation therapy\n5. Known genetic disorder or chromosomal abnormality\n6. BMI \\>40Kg\u002Fm2\n7. Currently using hormonal contraception or hormone replacement therapy",{"count":658,"type":23},2059,"This study aims to explore the potential correlation between decreased ovarian reserve and previous history of early miscarriage.",[661,662,663,664],"Infertility, Female","Miscarriage","Miscarriage, Recurrent","IVF",[666,667,664],"miscarriage","infertility",{"date":294,"type":34},{"date":670,"type":34},"2023-09-09",{"date":538,"type":23},{"name":540,"class":120},{"id":674,"slug":675,"hasResults":12,"nctId":676,"briefTitle":677,"officialTitle":678,"acronym":4,"eligibilityCriteria":679,"healthyVolunteers":128,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":680,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":682,"conditions":683,"keywords":684,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":693,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":121},"100475618","descriptive-analysis-of-serum-immunological-markers-during-an-euploid-frozen-embryo-transfer-in-a-natural-cycle-100475618","NCT05473273","Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.","Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle (NC).","Inclusion Criteria:\n\n* Women aged 18 years to 40 years\n* Having at least one good quality (grade A or B for inner mass cell and trophectoderm) day 5 or 6 chromosomally normal cryopreserved blastocyst available for transfer\n* Single embryo transfer in a natural cycle (NC) or an Hormone Replacement Therapy (HRT) protocol\n* Fresh ejaculate used for fertilization\n\nExclusion Criteria:\n\n* Body mass index lower than 18.5 or equal or higher than 29 kg\u002Fm2\n* Endometriosis or adenomyosis suspected by medical history (dysmenorrhea, dyspareunia, heavy or prolonged menstrual bleeding (\\> 8 days), chronic pelvic pain, catamenial rectal or bladder symptoms) or diagnosed by imaging (magnetic resonance imaging or ultrasonography)\n* Uterine abnormalities\n* Hydrosalpinx\n* Insulin resistance or diabetes mellitus diagnosed by HbA1c 5.7 %\n* Antiphospholipid syndrome\n* Polycystic ovarian syndrome according to Rotterdam criteria: presence of at least two of the following: irregular cycles (\\\u003C 21 or \\> 35 days or \\\u003C 8 cycles a year), biochemical or clinical hyperandrogenism, ovarian ultrasound morphology (\\> 20 follicles per ovary on transvaginal scan) or Anti-mullerian hormone \\> 5,98 ng\u002Fml\n* History of recurrent miscarriage, defined as the loss of 2 or more pregnancies according to ESHRE guidelines\n* History of implantation failure, considered as the lack of pregnancy after the transfer of 2 good-quality (grade A or B for inner mass cell and trophectoderm (29)) euploid embryos\n* History or suspicion of Asherman syndrome\n* Autoimmune disease\n* Couple first degree consanguineous",{"count":681,"type":23},40,"To describe the peripheral serum levels of the anti-inflammatory cytokines IL-4 (Interleukin-4), IL-10 (Interleukin-10), TGF-ß1 (Transforming Growth Factor beta1), the pro-inflammatory cytokines IL-17 (Interleukin-17), IFγ (Interferon Gamma) and the immune mediator PIBF (Progesterone-Induced Blocking Factor) along a single frozen euploid blastocyst transfer in a natural cycle (NC) or Hormone Replacement Therapy (HRT).",[661],[685,686,687,688,689,690,691,692],"infertilty","ivf","progesterone","estradiol","cytokines","immunology","Pharmacological effect of drugs","hormones",{"date":294,"type":34},{"date":695,"type":34},"2023-04-24",{"date":697,"type":23},"2026-12-30",{"name":540,"class":120},{"id":700,"slug":701,"hasResults":12,"nctId":702,"briefTitle":703,"officialTitle":704,"acronym":4,"eligibilityCriteria":705,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":706,"targetDuration":708,"studyType":53,"phases":4,"briefSummary":709,"conditions":710,"keywords":713,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":719,"lastUpdatePostDateStruct":720,"startDateStruct":721,"completionDateStruct":723,"leadSponsor":725,"locationsCount":727},"100075056","pompe-disease-registry-protocol-100075056","NCT00231400","Pompe Disease Registry Protocol","Pompe Disease Registry","Inclusion Criteria:\n\nAll patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and\u002For documentation of 2 GAA gene mutations.\n\nExclusion Criteria:\n\nThere are no exclusion criteria in this Registry",{"count":707,"type":23},2000,"5 Years","The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development\u002Freimbursement, and for other research and non-research related purposes.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Pompe disease population.\n* To evaluate the long-term effectiveness of alglucosidase alfa.",[711,712],"Glycogen Storage Disease Type II","Pompe Disease",[714,715,712,716,717,718],"Glycogen Storage Disease Type II (GSD-II)","GSD-II","Pompe Disease (late-onset)","Acid Maltase Deficiency Disease","Glycogenosis II","2026-06-19",{"date":565,"type":34},{"date":722,"type":34},"2004-09-15",{"date":724,"type":23},"2034-01-31",{"name":726,"class":41},"Genzyme, a Sanofi Company",272,""]